Cargando…

Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics

Recently, cyclin-dependent kinase (CDK) 4/6 inhibitors have been widely used to treat advanced hormone receptor-positive breast cancer. Despite promising clinical outcomes, almost all patients eventually acquire resistance to CDK4/6 inhibitors. Here, we screened genes associated with palbociclib res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pandey, Kamal, Lee, Eunbyeol, Park, Nahee, Hur, Jin, Cho, Young Bin, Katuwal, Nar Bahadur, Kim, Seung Ki, Lee, Seung Ah, Kim, Isaac, An, Hee Jung, Hwang, Sohyun, Moon, Yong Wha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912104/ https://www.ncbi.nlm.nih.gov/pubmed/33504001 http://dx.doi.org/10.3390/genes12020159

Ejemplares similares

Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase
por: Pandey, Kamal, et al.
Publicado: (2022)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model
por: Park, Nahee, et al.
Publicado: (2020)

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
por: Hur, Jin, et al.
Publicado: (2021)

Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer
por: Jeong, Yeong Gyu, et al.
Publicado: (2023)

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
por: Pandey, Kamal, et al.
Publicado: (2019)

The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma
por: Horbinski, Craig, et al.
Publicado: (2021)

Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
por: Katuwal, Nar Bahadur, et al.
Publicado: (2023)

CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator
por: Moon, Yong Wha, et al.
Publicado: (2017)

SIRT3 deregulation is linked to mitochondrial dysfunction in Alzheimer's disease
por: Lee, Junghee, et al.
Publicado: (2017)

Preclinical Drug Response Metric Based on Cellular Response Phenotype Provides Better Pharmacogenomic Variables with Phenotype Relevance
por: Kim, Sanghyun, et al.
Publicado: (2021)

Acute Lymphoblastic Leukemia in a Patient Treated with Letrozole and Palbociclib
por: Park, Jin Hyun, et al.
Publicado: (2019)

Palbociclib in the treatment of recurrent ovarian cancer
por: Lee, Dai Wee, et al.
Publicado: (2020)

Identification of MYH9 as a key regulator for synoviocyte migration and invasion through secretome profiling
por: Lee, Saseong, et al.
Publicado: (2023)

A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas
por: Hidalgo, Manuel, et al.
Publicado: (2022)

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
por: Lee, Cha Len, et al.
Publicado: (2023)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Combination of palbociclib and radiotherapy for glioblastoma
por: Whittaker, Shane, et al.
Publicado: (2017)

Palbociclib-Induced Liver Failure
por: Atallah, Rami, et al.
Publicado: (2020)

Role of high-temperature requirement serine protease A 2 in rheumatoid inflammation
por: Jeong, Gi Heon, et al.
Publicado: (2023)

Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor–Positive Metastatic Breast Cancer
por: Kim, Seul-Gi, et al.
Publicado: (2023)

Deregulation of CREB Signaling Pathway Induced by Chronic Hyperglycemia Downregulates NeuroD Transcription
por: Cho, In-Su, et al.
Publicado: (2012)

Palbociclib in breast cancer neoadjuvant setting
por: Duarte, Sílvia Alexandra Cabral, et al.
Publicado: (2021)

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
por: Bollard, Julien, et al.
Publicado: (2017)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
por: Park, Yeon Hee, et al.
Publicado: (2023)

Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies
por: Moon, Yong Wha, et al.
Publicado: (2023)

Considerations for patient selection: Prepectoral versus subpectoral implant-based breast reconstruction
por: Yang, Jun Young, et al.
Publicado: (2019)

Pharmacokinetic evaluation of radiolabeled intraocular anti‐CLEC14a antibody in preclinical animal species and application in humans
por: Park, Sohyun, et al.
Publicado: (2022)

Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab, Moataz, et al.
Publicado: (2016)

Neutropenia due to palbociclib: A word of caution?
por: Pramanik, Raja, et al.
Publicado: (2016)

Palbociclib: COVID-19 infection: case report
Publicado: (2020)

Lysosomal trapping of palbociclib and its functional implications
por: Llanos, Susana, et al.
Publicado: (2019)

Palbociclib: Myelosuppression and gastrointestinal reactions: case report
Publicado: (2022)

A single institution experience with palbociclib toxicity requiring dose modifications
por: Gong, Jun, et al.
Publicado: (2017)

Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer
por: Lee, Ju-Eun, et al.
Publicado: (2023)

MEK blockade overcomes the limited activity of palbociclib in head and neck cancer
por: Fang, Zhenghuan, et al.
Publicado: (2020)

The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson’s disease mouse model
por: Lee, Saebom, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rmi3t8791imkeergc5eijnos7l